Amber L Beitelshees
University of Maryland, Baltimore
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Amber L Beitelshees as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:33 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06813014 · Pharmacogenetics of Response to Sitagliptin (PRS)University of Maryland, Baltimore · not yet recruiting · Diabetes · principal investigator
- Ph1NCT05071898 · Pharmacogenetics of Response to GLP1R AgonistsUniversity of Maryland, Baltimore · recruiting · Obesity, Diabetes Type 2 · principal investigator
- Ph4NCT00925119 · Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 DiabetesUniversity of Maryland, Baltimore · terminated · Diabetes Mellitus, Type 2 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:33 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Pharmacogenetics of the Response to a GLP1R AgonistR01DK130238 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2022 to 2026 · $672,063 awarded in 2026Same name and institution; not confirmed by an ID
- Comparing Direct and Indirect Methods for Cascade Screening in Familial Hypercholesterolemia (FH) and Long QT Syndrome (LQTS)R01HL163514 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2022 to 2025 · $696,129 awarded in 2025Same name and institution; not confirmed by an ID
- Genetics of Response to CanagliflozinR01DK118942 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2018 to 2022 · $639,301 awarded in 2022Same name and institution; not confirmed by an ID
- A Community-Based Approach to Overcoming Barriers to Cascade Screening for Long QT SyndromeR21HG010412 · NHGRI · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2018 to 2019 · $235,342 awarded in 2019Same name and institution; not confirmed by an ID
- Uncoupling Protein Polymorphisms and Cardiometabolic Responses to Beta-BlockersK23HL091120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · fiscal years 2008 to 2012 · $132,842 awarded in 2012Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:33 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.JACC Cardiovasc Interv · 2018252 citationsRCR 10.5
- Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.Am Heart J · 2009104 citationsRCR 2.6
- Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes.Circ Cardiovasc Genet · 201394 citationsRCR 2.7
- Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.J Hypertens · 201357 citationsRCR 1.8
- KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).Pharmacogenet Genomics · 200754 citationsRCR 1.3
- Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics.Clin Pharmacol Ther · 201352 citationsRCR 1.7
- Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.Hypertension · 201051 citationsRCR 1.3
- Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.Circ Cardiovasc Genet · 201246 citationsRCR 1.3
- 36 citationsRCR 0.9
- Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).Circ Cardiovasc Genet · 201033 citationsRCR 0.9